Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Long-Term Debt Repayments (2016 - 2018)

Historic Long-Term Debt Repayments for Gyre Therapeutics (GYRE) over the last 10 years, with Q1 2018 value amounting to $5.1 million.

  • Gyre Therapeutics' Long-Term Debt Repayments fell 2473.34% to $5.1 million in Q1 2018 from the same period last year, while for Dec 2018 it was $5.1 million, marking a year-over-year decrease of 6450.62%. This contributed to the annual value of $5.1 million for FY2018, which is 6450.62% down from last year.
  • Per Gyre Therapeutics' latest filing, its Long-Term Debt Repayments stood at $5.1 million for Q1 2018, which was down 2473.34% from $403000.0 recorded in Q4 2017.
  • In the past 5 years, Gyre Therapeutics' Long-Term Debt Repayments ranged from a high of $10.3 million in Q4 2016 and a low of $218000.0 during Q1 2014
  • In the last 5 years, Gyre Therapeutics' Long-Term Debt Repayments had a median value of $634000.0 in 2016 and averaged $2.6 million.
  • In the last 5 years, Gyre Therapeutics' Long-Term Debt Repayments skyrocketed by 108945.54% in 2016 and then crashed by 9607.4% in 2017.
  • Gyre Therapeutics' Long-Term Debt Repayments (Quarter) stood at $478000.0 in 2014, then soared by 80.54% to $863000.0 in 2015, then surged by 1089.46% to $10.3 million in 2016, then crashed by 96.07% to $403000.0 in 2017, then skyrocketed by 1161.04% to $5.1 million in 2018.
  • Its Long-Term Debt Repayments stands at $5.1 million for Q1 2018, versus $403000.0 for Q4 2017 and $282000.0 for Q3 2017.